China accepts regulatory filing for ALK allergy tablet
ALK says 100 million people suffer house dust mite allergies in China but only 500,000 patients receive allergy immunotherapy.
by marketwire, translated by daniel pedersen
ALK has announced that the National Medical Products Administration (NMPA) in China has accepted a market authorization application for the allergy firm’s house dust mite tablet treatment.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
ALK forecasts lower growth in 2023 than strong 2022 result
For subscribers
.jpg&w=384&q=75)
